AUS
NZ
UK
CA
USA
IND
Highlights
- RAD has dosed the first patient in its U.S. Phase 2b clinical trial of 18F-RAD101 for suspected recurrent brain metastases.
- The Phase 2b study aims to evaluate the diagnostic accuracy of 18F-RAD101 in 30 participants with confirmed recurrent brain metastases from solid tumours of different origins.
- Earlier Phase 2a data from Imperial College London showed consistent tumour uptake with 18F-RAD101 across different tumour types.
- Topline data is expected in the second half of 2025.
Radiopharm Theranostics (ASX:RAD, Nasdaq:RADX) has dosed the first patient in its U.S. Phase 2b imaging study of 18F-RAD101 for suspected recurrent brain metastases from various solid tumours.
The U.S.-based Phase 2b clinical trial is a multi-centre, open-label, single-arm study that aims to assess the diagnostic performance of 18F-RAD101 in patients with confirmed recurrent brain metastases originating from different solid tumours. The study will involve 30 participants, with the primary objective to evaluate the concordance between lesions detected by 18F-RAD101 and those identified through conventional imaging methods, particularly MRI with gadolinium, in patients with suspected recurrent brain metastases.
Data from the Imperial College London's Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases reported encouraging outcomes with 18F-RAD101 demonstrating significant tumour uptake that was consistent across different tumour origins.
RAD shares were trading at AU$0.021 per share at the time of writing on 28 April 2025.
